Cubist Systematic Strategies LLC Takes $461,000 Position in OrthoPediatrics Corp. (NASDAQ:KIDS)

Cubist Systematic Strategies LLC acquired a new stake in shares of OrthoPediatrics Corp. (NASDAQ:KIDS) during the fourth quarter, HoldingsChannel reports. The firm acquired 19,903 shares of the company’s stock, valued at approximately $461,000.

Other institutional investors and hedge funds have also modified their holdings of the company. R Squared Ltd bought a new stake in shares of OrthoPediatrics during the fourth quarter valued at approximately $48,000. KLP Kapitalforvaltning AS bought a new stake in OrthoPediatrics in the fourth quarter valued at $79,000. AlphaCentric Advisors LLC bought a new stake in OrthoPediatrics in the fourth quarter valued at $171,000. Wells Fargo & Company MN grew its position in OrthoPediatrics by 31.1% in the fourth quarter. Wells Fargo & Company MN now owns 9,853 shares of the company’s stock valued at $228,000 after acquiring an additional 2,338 shares during the period. Finally, HighTower Advisors LLC bought a new stake in OrthoPediatrics in the fourth quarter valued at $268,000. 69.05% of the stock is currently owned by institutional investors.

OrthoPediatrics Trading Up 0.9%

NASDAQ KIDS opened at $23.07 on Friday. OrthoPediatrics Corp. has a 12 month low of $20.25 and a 12 month high of $35.99. The stock has a 50-day simple moving average of $22.86 and a 200 day simple moving average of $23.99. The company has a market capitalization of $560.30 million, a PE ratio of -18.76 and a beta of 1.09. The company has a current ratio of 7.17, a quick ratio of 3.68 and a debt-to-equity ratio of 0.19.

OrthoPediatrics (NASDAQ:KIDS) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.13). OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. The business had revenue of $52.41 million during the quarter, compared to the consensus estimate of $51.68 million. Research analysts forecast that OrthoPediatrics Corp. will post -0.93 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Needham & Company LLC reiterated a “buy” rating and issued a $42.00 price target on shares of OrthoPediatrics in a research report on Thursday, May 8th. Piper Sandler lowered their price target on OrthoPediatrics from $40.00 to $30.00 and set an “overweight” rating on the stock in a research report on Thursday, May 8th. Truist Financial lowered their price target on OrthoPediatrics from $26.00 to $24.00 and set a “hold” rating on the stock in a research report on Friday, April 11th. Stifel Nicolaus reduced their price objective on OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, March 5th. Finally, Lake Street Capital started coverage on OrthoPediatrics in a research note on Monday, April 7th. They issued a “buy” rating and a $37.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $35.83.

Insiders Place Their Bets

In related news, General Counsel Daniel J. Gerritzen sold 5,310 shares of the stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total transaction of $132,006.60. Following the completion of the transaction, the general counsel now directly owns 110,767 shares in the company, valued at approximately $2,753,667.62. This trade represents a 4.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO David R. Bailey sold 6,620 shares of the stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total value of $164,573.20. Following the transaction, the chief executive officer now owns 319,155 shares of the company’s stock, valued at approximately $7,934,193.30. The trade was a 2.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 23,732 shares of company stock worth $589,978 over the last ninety days. 32.70% of the stock is currently owned by corporate insiders.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.